Myopia Clinical Trial
Official title:
Effect of Using Myopia Prediction Algorithm on Myopia School-aged Children's Eye Refraction in China: a Multi-center Randomized Control Trial
In this study, the investigators aim to perform a prospective, randomized controlled study to compare the myopia development between myopia children using myopia prediction algorithm and myopia children without using myopia prediction algorithm
Status | Recruiting |
Enrollment | 2138 |
Est. completion date | November 30, 2021 |
Est. primary completion date | November 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 8 Years to 10 Years |
Eligibility |
Inclusion Criteria: - Children aged 8-10 - Has the record of eye refraction examined in the past year, SER<-0.5D - Current BCVA=0.8, SER<-0.5D, Astigmatism less than 1.50 D, anisometropia less than 1.50 D - Written informed consents provided Exclusion Criteria: - Definitive diagnosis of other diseases except for refractive error - Previous eye surgery - Previous usage of orthokeratology lenses and atropine - Unwilling to participate in this trial |
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Ophthalmic Centre | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of SER development of at least -1.0 dioptres (D) | SER: spherical equivalent refraction, sphere + ½ 360 cylinder; SER development of at least -1.0 dioptres: SER2 - SER1=-0.5D; SER1: SER at baseline; SER2: SER up to 2 year | up to 2 year | |
Primary | Incidence of SER development of at least -0.5 dioptres (D) | SER: spherical equivalent refraction, sphere + ½ 360 cylinder; SER development of at least -0.5 dioptres: SER2 - SER1=-0.5D; SER1: SER at baseline; SER2: SER up to 1 year | up to 1 year | |
Secondary | Changes in SER \ and AL | Changes in SER \ and AL will be calculated; AL: axial length | Up to 1 year | |
Secondary | Changes in SER \ and AL | Changes in SER \ and AL will be calculated; AL: axial length | Up to 2 year | |
Secondary | Changes in proportion of children using atropine | Changes in proportion of children using atropine will be calculated | Up to 1 year | |
Secondary | Changes in proportion of children using atropine | Changes in proportion of children using atropine will be calculated | Up to 2 year | |
Secondary | Changes in proportion of children using orthokeratology lenses | Changes in proportion of children using orthokeratology lenses will be calculated | Up to 1 year | |
Secondary | Changes in proportion of children using orthokeratology lenses | Changes in proportion of children using orthokeratology lenses will be calculated | Up to 2 year | |
Secondary | Changes in proportion of children using spectacles | Changes in proportion of children using spectacles will be calculated | Up to 1 year | |
Secondary | Changes in proportion of children using spectacles | Changes in proportion of children using spectacles will be calculated | Up to 2 year | |
Secondary | Changes in child's average outdoor activity time per day | Changes in child's average outdoor activity time per day will be calculated | Up to 1 year | |
Secondary | Changes in child's average outdoor activity time per day | Changes in child's average outdoor activity time per day will be calculated | Up to 2 year | |
Secondary | Changes in child's average screen time per day | Changes in child's average screen time per day will be calculated | Up to 1 year | |
Secondary | Changes in child's average screen time per day | Changes in child's average screen time per day will be calculated | Up to 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04923841 -
Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine
|
N/A | |
Active, not recruiting |
NCT04080128 -
Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control
|
N/A | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Completed |
NCT04604405 -
Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation
|
N/A | |
Recruiting |
NCT05594719 -
The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow
|
N/A | |
Completed |
NCT05594732 -
The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow
|
N/A | |
Completed |
NCT04492397 -
Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI)
|
N/A | |
Completed |
NCT04536571 -
Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses
|
N/A | |
Completed |
NCT06046209 -
Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens
|
N/A | |
Recruiting |
NCT06344572 -
Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia
|
Phase 3 | |
Recruiting |
NCT05611294 -
Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction
|
N/A | |
Completed |
NCT05656885 -
Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses
|
N/A | |
Active, not recruiting |
NCT05534022 -
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.
|
N/A | |
Completed |
NCT03934788 -
the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens
|
N/A | |
Completed |
NCT03701516 -
Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2
|
N/A | |
Completed |
NCT05538754 -
Post-Market Evaluation of the EVO ICL
|
N/A | |
Completed |
NCT03139201 -
Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens
|
N/A | |
Completed |
NCT02555722 -
Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear
|
N/A | |
Not yet recruiting |
NCT06009458 -
Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
|
N/A | |
Recruiting |
NCT05548478 -
Corneal Endothelial Cell Injury Induced by Mitomycin-C
|
N/A |